查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138337

富血小板血漿 (PRP)-2022-2029 的全球市場

Global Platelet Rich Plasma Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

新的富血小板血漿 (PRP) 療法可用於各種應用，預計將推動市場增長。

富血小板血漿療法被認為是治療和治療的絕佳新選擇。由於在整容手術中的應用越來越多，富血小板血漿療法最近已廣泛用於臨床環境。皮膚科醫生和整形外科醫生還利用富含血小板的血漿的自然癒合能力來改善皮膚的外觀和健康。它也用於面部年輕化，其效果可期。還使用純富含血小板的血漿，因為它具有更快的組織形成和修復、更快的癒合和更好的整體性能等優點。此外，由於副作用小、免疫和過敏反應風險低，預計血小板減少血漿市場將迅速上升。因此，上述聲明預計將在預測期內推動市場。

限制

富血小板血漿療法價格波動大，傷口護理設備報銷政策優惠。此外，質量控制問題、實驗室檢查結果以及與富含血小板的血漿療法相關的缺陷會導致治療部位的神經損傷、組織損傷和感染。因此，預計上述陳述將在預測期內阻礙市場。

COVID-19 影響分析

COVID-19 大流行對市場產生了積極影響。沒有特定的抗病毒藥物可用於治療。在 2019 年冠狀病毒病 (COVID-19) 中經常觀察到血栓栓塞的並發症。另一方面，COVID-19 與血小板失調有關。 COVID-19 的不良後果與基礎血小板活化增加和血小板反應降低有關，隨著時間的推移，這種情況會惡化。隨著 COVID-19 的爆發，對富血小板血漿療法的需求顯著增加，因為血小板在消除呼吸系統疾病和維持肺功能方面發揮著重要作用，因此將富血小板血漿療法用於冠狀病毒治療。例如，作為適應性免疫療法的代表的恢復期血漿（CP）療法已被應用於預防和治療多種傳染病一個多世紀。在過去的二十年裡，CP 療法成功地治療了 SARS、MERS 和 2009 年 H1N1 大流行，具有令人滿意的療效和安全性。因此，這是為了在預測期內提振富含血小板的血漿市場。

行業分析

富含血小板的血漿市場根據各種行業因素（例如未滿足的需求、定價分析、供應鏈分析和監管分析）對市場進行深入分析。

全球富血小板血漿市場報告包含大約 45 多個市場數據表、40 多個數字和 180 頁。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按類型劃分的市場細分
  • 按應用劃分的市場細分
  • 按產地劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 由於富血小板血漿 (PRP) 療法的興起，該市場有望增長，該療法用於各種應用。
    • 約束因素
      • 與富含血小板的血漿相關的缺點預計會阻礙市場增長。
    • 機會
    • 影響分析

第五章行業分析

  • 供應鏈分析
  • 定價分析
  • 法律法規分析
  • 未滿足的需求

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 富含血小板的純血漿
  • 白細胞增多型PRP
  • 富含白細胞的纖維蛋白
  • 其他

第 8 章按應用程序

  • 骨科
  • 美容外科/皮膚科
  • 神經內科
  • 循環區
  • 眼科
  • 其他

第 9 章按原產地

  • 自體 PRP
  • 自體 PRP
  • 異基因 PRP
  • 其他

第 10 章，最終用戶

  • 醫院
  • 診所
  • 其他

第 11 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 12 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 13 章全球富血小板血漿市場 - 公司簡介

  • Zimmer Biomet
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Johnson & Johnson（DePuy Synthes）
  • Arthrex Inc.
  • Terumo BCT Inc.
  • Celling BioSciences
  • APEX Biologix
  • Juventix
  • Dr. PRP America
  • Stryker
  • Ycellbio Medical Co., Ltd (*未詳盡列出)

第 14 章數據M

簡介目錄
Product Code: DMMD1333

Market Overview

Platelet Rich Plasma Market is expected to grow at a CAGR of 13.88% during the forecasting period (2022-2029).

Platelet-rich plasma (PRP) is derived from blood. It's made when human blood is spun down and platelet-rich plasma, which has a higher concentration of platelets than normal, is extracted. Platelets assist in blood clotting and assist tendons, muscles, and ligaments repair faster. PRP is used in various operations, including rotator cuff augmentation and tendon repair. Healing factors and connective tissue development is abundant in platelets.

Market Dynamics

Emerging platelet-rich plasma (PRP) therapy utilized for various applications is expected to drive market growth.

Platelet-rich plasma therapy is considered a superior emerging choice for therapy and procedures. Platelet-rich plasma therapy has recently been widely used in clinical settings, owing to increased use in cosmetic operations. In addition, dermatologists and plastic surgeons use platelet-rich plasma's natural healing qualities to improve the appearance and health of the skin. Its usage in face rejuvenation has also yielded promising effects. Pure platelet-rich plasma is also used because of its benefits, such as faster tissue formation and repair, faster healing, and greater overall performance. Also, with fewer side effects and a lower risk of immunological reaction and allergic reactions, the Platelet Rich Plasma market is expected to rise rapidly. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

There is high price variability in platelet-rich plasma therapy and favorable reimbursement policies in wound care equipment. Furthermore, issues with quality control and test findings and drawbacks associated with platelet-rich plasma therapy induce nerve damage, tissue damage, and infection in the treatment region. Therefore, the market is expected to get hampered in the forecast period from the above statements.

COVID-19 Impact Analysis

The COVID-19 pandemic had a positive impact on the market. There are no specific antiviral agents available for its treatment. Thromboembolic complications are frequently observed in Coronavirus disease 2019 (COVID-19). In contrast, COVID-19 is linked to platelet dysregulation. An adverse outcome in COVID-19 was associated with increased basal platelet activation and diminished platelet responses, which aggravated over time. Due to the covid-19 outbreak, platelet-rich plasma therapy was used to treat coronavirus as platelets play a vital role in eliminating respiratory disorders and maintaining the functioning of the lungs due to the demand for platelet-rich plasma therapy has significantly increased. For instance, Convalescent plasma (CP) therapy, classic adaptive immunotherapy, has been applied to prevent and treat many infectious diseases for more than one century. Over the past two decades, CP therapy successfully treated SARS, MERS, and the 2009 H1N1 pandemic with satisfactory efficacy and safety. Thus, this is due to boosting the forecast period's platelet-rich plasma market.

Industry Analysis

The platelet rich plasma market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

Segment Analysis

Pure Platelet Rich Plasma segment is expected to hold the largest market share in the platelet-rich plasma market.

The pure platelet-rich plasma segment accounted for the largest market share in 2021. The segment benefits because it has rapid healing, tissue repair and production, and general function improvement, which have enhanced its demand across several treatment business spaces, adding to segment expansion. In pure PRP therapeutic approaches, entities in the market are paying attention to effectively eliminating dangers and unwanted effects, such as allergic or immunological reactions. PRP's present off-label use has prompted numerous manufacturers worldwide to produce various sorts of products, owing to its tremendous promise in treating various chronic illnesses. For instance, Celling Biosciences is dedicated to the scientific understanding and therapeutic application of autologous cell therapy, which includes ART PRP product which is widely used in orthopedic and sports medicine to relieve pain through the natural promotion of healing in musculoskeletal diseases such as tendonitis, arthritis, ligament sprains, and tears. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North American region is expected to hold the largest market share in the global platelet rich plasma market.

In 2021, North America accounted for the highest revenue share. The increasing number of cosmetic surgeries, high awareness about platelet-rich plasma-based treatments, technological advancement, well-established infrastructure, product launches and approvals by the market players are some factors that the market is expected to boost in the forecast period. For instance, with approximately four million cosmetic treatments performed in 2020, the United States will have the highest number of cosmetic procedures globally. Over the last decade, the number of surgical and nonsurgical cosmetic treatments performed in the United States has increased, from over 1.6 million in 1997 to over 5.5 million in 2020. Moreover, EmCyte acquired Cellmedix Holdings LLC in February 2020, acquiring all of the latter's assets, including its proprietary product system, the Centrepid Platelet Concentrator. EmCyte's product development skills and intellectual property profile will be enhanced as a result of this strategic purchase. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the platelet-rich plasma market are Zimmer Biomet, Johnson & Johnson (DePuy Synthes), Arthrex Inc., Terumo BCT Inc., Celling BioSciences , APEX Biologix, Juventix, Dr. PRP America, Stryker and Ycellbio Medical Co., Ltd.

Johnson & Johnson (DePuy Synthes):

Overview:

Johnson & Johnson (DePuy Synthes) designs, manufacture, and markets various orthopedic and neurological devices globally. The company is involved in developing medical devices for diagnosing damaged joints and repairing reconstructing skeletal injuries. It has a comprehensive portfolio of orthopedic products and neuro products, and it focuses on the therapeutic areas of spinal care, orthopedics, sports medicine, and neurosciences. It offers products, services, programs, and R&D capabilities to advance patient care and adds clinical and economic value to healthcare systems. In many countries, the company operates under the name of Johnson and Johnson.

Product Portfolio:

PEAK Platelet Rich Plasma System: The PEAK Platelet Rich Plasma System represents an option in autologous cellular therapies featuring a vertical roto centrifugation process. The proprietary technology consistently delivers 3 ml of 7.8x high-concentration platelet rich plasma (PRP) from 27 ml of whole blood within 2.5 minutes.

The global Platelet rich plasma market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Origin
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Emerging platelet-rich plasma (PRP) therapy utilized for various applications is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The drawbacks associated with platelet-rich plasma are expected to hamper market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Pure Platelet Rich Plasma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Leukocyte Rich PRP
  • 7.4. Leukocyte-Rich Fibrin
  • 7.5. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Orthopedics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Cosmetic Surgery and Dermatology
  • 8.4. Neurology
  • 8.5. Cardiology
  • 8.6. Ophthalmology
  • 8.7. Others

9. By Origin

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 9.1.2. Market Attractiveness Index, By Origin Segment
  • 9.2. Autologous PRP*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Homologous PRP
  • 9.4. Allogeneic PRP
  • 9.5. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Clinics
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Origin
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Global Platelet-rich Plasma Market- Company Profiles

  • 13.1. Zimmer Biomet*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Johnson & Johnson (DePuy Synthes)
  • 13.3. Arthrex Inc.
  • 13.4. Terumo BCT Inc.
  • 13.5. Celling BioSciences
  • 13.6. APEX Biologix
  • 13.7. Juventix
  • 13.8. Dr. PRP America
  • 13.9. Stryker
  • 13.10. Ycellbio Medical Co., Ltd(*LIST NOT EXHAUSTIVE)

14. DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us